Search results for "Viral Load"

showing 10 items of 232 documents

The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients

2017

Mixed cytomegalovirus (CMV) infections are associated with delayed viral clearance in solid organ transplant recipients. We investigated whether this could be extrapolated to allogeneic stem cell transplant (allo-SCT) recipients. A total of 48 plasma specimens, obtained during 29 episodes of active CMV infection in 25 non-consecutive allo-SCT patients, were analysed. Baseline blood specimens, drawn shortly prior to the inception of pre-emptive antiviral therapy (pre-treatment specimen; n=29), as well as follow-up samples obtained either after the initiation of antiviral therapy (post-treatment specimen; n=15) or during recurrent episodes (n=4) were analysed. Plasma CMV DNA loads were quanti…

AdultMale0301 basic medicine030106 microbiologyCytomegalovirusBiologymedicine.disease_causeAntiviral AgentsVirus03 medical and health sciencesVirologyGenotypemedicineHumansTransplantation HomologousGenotypingAgedBase SequenceGenetic VariationHigh-Throughput Nucleotide Sequencingvirus diseasesCytomegalovirusSequence Analysis DNACmv dnaemiaMiddle AgedViral LoadVirologyHypervariable region030104 developmental biologyCytomegalovirus InfectionsDNA ViralImmunologyFemalePopulation diversityStem cellStem Cell TransplantationJournal of General Virology
researchProduct

Assessing the risk of cytomegalovirus DNAaemia in allogeneic stem cell transplant recipients by monitoring oxidative-stress markers in plasma

2017

The level of antioxidants, such as thiol-containing tripeptide glutathione (GSH), in cytomegalovirus (CMV)-infected cells is notably increased. We previously showed that GSH levels in plasma, as measured by untargeted 1H nuclear magnetic resonance, are higher in allogeneic stem cell transplant (allo-SCT) recipients who subsequently develop CMV viraemia. We hypothesized that the net level of oxidative-stress markers present in plasma may be reduced in patients who develop CMV DNAaemia compared to those who do not. We serially monitored the levels of malondialdehyde (MDA) and carbonylated proteins (CPs) early after allo-SCT and assessed whether they could predict the occurrence of CMV DNAaemi…

AdultMale0301 basic medicineCongenital cytomegalovirus infectionCytomegalovirusBiologymedicine.disease_causeAntioxidantsProtein Carbonylation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMalondialdehydeVirologymedicineHumansViremiaAgedArea under the curvevirus diseasesGlutathioneMiddle AgedViral LoadMalondialdehydemedicine.diseaseGlutathioneVirologyConfidence intervalOxidative Stress030104 developmental biologyROC CurvechemistryHematologic Neoplasms030220 oncology & carcinogenesisCytomegalovirus InfectionsDNA ViralImmunologyBiomarker (medicine)FemaleStem cellOxidative stressStem Cell TransplantationJournal of General Virology
researchProduct

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 …

2020

Our aim was to evaluate the association between recent eGFR values and risk of switching from TDF to TAF or dual therapy (DT) in real life. HIV-positive patients achieving HIV-RNA ≤50 copies/mL for the first time after starting a TDF-based regimen were included. Kaplan–Meier (KM) curves and Cox regression models were used to estimate the time from TDF to switch to TAF or DT. 1486 participants were included: median (IQR) age 36 (30–42) years; baseline CKD-EPI eGFR 99.92 (86.47–111.4) mL/min/1.73m2. We observed a consistently higher proportion of people with HIV-RNA ≤50 copies/mL who switched from TDF to TAF rather than to DT. By competing risk analysis, at 2 years from baseline, the probabil…

AdultMale0301 basic medicineMicrobiology (medical)Dual therapymedicine.medical_specialtyTenofovirAnti-HIV Agents030106 microbiologyUrologyRenal functionTenofovir alafenamide03 medical and health sciences0302 clinical medicineHiv infectedeGFRmedicineHumansPharmacology (medical)Prospective StudiesTenofovir alafenamide030212 general & internal medicineDual therapyTenofovirAcquired Immunodeficiency SyndromeAlanineDrug SubstitutionProportional hazards modelbusiness.industryAdenineHIVGeneral MedicineViral LoadAntiretroviral therapyRegimenInfectious DiseasesHIV-1Drug Therapy CombinationFemaleTenofovir disoproxil fumarate.businessViral loadGlomerular Filtration Ratemedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals

2018

The emergence of resistance-associated substitutions (RASs) can compromise the high efficacy of direct-acting antivirals (DAAs). Little is known about RASs selection at very early time points during DAA treatment. Therefore, we analyzed the potential emergence of RASs immediately after therapy initiation. Samples of 71 patients treated with different DAAs were collected at baseline, during therapy (hours 4 and 8; days 1-7; weeks 2-4) or until target not detected. HCV-RNA levels were determined by qPCR, and RASs were detected by deep sequencing. Sixty-three (89%) patients achieved a sustained virological response (SVR), 7 (10%) relapsed, and 1 (1%) experienced a breakthrough. Almost all non-…

AdultMale0301 basic medicinemedicine.medical_specialtySustained Virologic ResponseHepatitis C virusHepacivirusViral quasispeciesReal-Time Polymerase Chain ReactionDIRECT ACTING ANTIVIRALSmedicine.disease_causeAntiviral AgentsGastroenterologyDeep sequencingVirological response03 medical and health sciences0302 clinical medicineRecurrenceGenetic EvolutionVirologyInternal medicineDrug Resistance ViralHumansMedicineProspective StudiesSelection GeneticAgedAged 80 and overHepatologybusiness.industryAntiviral therapyvirus diseasesHepatitis C ChronicMiddle AgedViral Loaddigestive system diseases030104 developmental biologyInfectious DiseasesAmino Acid SubstitutionRNA ViralFemale030211 gastroenterology & hepatologySensitivity limitbusinessJournal of Viral Hepatitis
researchProduct

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

2012

Albinterferon alfa-2b (albIFN) is a fusion protein of recombinant human albumin/recombinant interferon (IFN)-α-2b, with ∼200-h half-life. Safety/efficacy of albIFN q4wk was evaluated in 391 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 2/3. Patients were randomized 3:4:4:4 to one of four open-label treatment groups: pegylated IFN (Peg-IFN)-α-2a 180 μg qwk or albIFN 900, 1200 or 1500 μg q4wk, plus oral ribavirin 800 mg/day, for 24 weeks. Primary efficacy endpoint was sustained virologic response (SVR; HCV RNA <20 IU/mL 24 weeks post-treatment). SVR rates were as follows: 85%, 76%, 76% and 78% with Peg-IFNα-2a and albIFN 900, 1200 and 1500 μg, respectively (P = NS); c…

AdultMaleANTIVIRAL TREATMENTGenotypeInterleukinsInterferon-alphaHepacivirusHepatitis C ChronicMiddle AgedViral LoadAntiviral AgentsAlbinterferon alfa-2bTreatment OutcomeAlbuminsHumansRNA ViralFemaleInterferonshepatitis CAlbinterferon alfa-2b; hepatitis c; ANTIVIRAL TREATMENT
researchProduct

Clinical evaluation of antiseptic mouth rinses to reduce salivary load of SARS-CoV-2

2021

AbstractMost public health measures to contain the COVID-19 pandemic are based on preventing the pathogen spread, and the use of oral antiseptics has been proposed as a strategy to reduce transmission risk. The aim of this manuscript is to test the efficacy of mouthwashes to reduce salivary viral load in vivo. This is a multi-centre, blinded, parallel-group, placebo-controlled randomised clinical trial that tests the effect of four mouthwashes (cetylpyridinium chloride, chlorhexidine, povidone-iodine and hydrogen peroxide) in SARS-CoV-2 salivary load measured by qPCR at baseline and 30, 60 and 120 min after the mouthrinse. A fifth group of patients used distilled water mouthrinse as a contr…

AdultMaleAdolescentScienceMouthwashesArticleMalalties transmissibles PrevencióYoung AdultDouble-Blind Methodstomatognathic systemHumansChildSalivaAgedMultidisciplinarySARS-CoV-2QRInfant NewbornCOVID-19InfantMiddle AgedViral LoadPlacebo EffectVirusViral infectionChild PreschoolRandomized controlled trialsAnti-Infective Agents LocalMedicineFemale
researchProduct

Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma.

2006

BACKGROUND Classic Kaposi sarcoma (CKS) is an inflammatory-mediated neoplasm that develops in the presence of KS-associated herpesvirus (KSHV) and immune perturbation. In the current study, the authors compared CKS cases with age-matched and sex-matched KSHV-seropositive controls without human immunodeficiency virus-1 infection and markers of viral control, blood counts, CD4-positive and CD8-positive lymphocytes, and serum β-2-microglobulin and neopterin levels. METHODS Viral loads were detected using real-time amplification of the KSHV-K6 and EBV-pol genes, anti-K8.1 (lytic) titers were detected by enzyme-linked immunoadsorbent assay, and antilatent nuclear antigen (LANA) titers were detec…

AdultMaleCancer ResearchHIV InfectionsHematocritmedicine.disease_causePeripheral blood mononuclear cellHerpesviridaechemistry.chemical_compoundAntigenRisk FactorsmedicineGammaherpesvirinaeHumansSarcoma KaposiAgedAged 80 and overmedicine.diagnostic_testbiologybusiness.industryAntibody titerNeopterinMiddle Agedbiology.organism_classificationKaposi Sarcoma human herpesvirus-8 immunityOncologychemistryItalyImmunologyMultivariate AnalysisDisease ProgressionHIV-1FemalebusinessViral loadBiomarkersCancer
researchProduct

Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients.

2012

Background Here, we assessed the presence of intrahepatic follicular helper T-cells (TFH) in a cohort of consecutive genotype 1 (G1) chronic hepatitis C (CHC) patients comprising non-responders (NRs), relapsers (RRs) or those with sustained virological response (SVR) to pegylated interferon and ribavirin, and tested their relation with the response to antiviral treatment. Methods A total of 78 patients with G1 CHC (30 SVR, 15 RR and 33 NR), comparable for sex, age, viral load and fibrosis were evaluated by immunohistochemistry for liver content of PD1+Bcl6+ TFH cells. The number of TFH cells in the immunostained sections was counted out of five representative high-power microscopic fields (…

AdultMaleGenotypeHepacivirusSettore MED/08 - Anatomia PatologicaAntiviral AgentsPolymorphism Single NucleotideBiomarkers PharmacologicalPolyethylene GlycolsCohort StudiesPharmacotherapyInterferonRibavirinGenotypeFollicular phaseHumansMedicinePharmacology (medical)liver biopsy Interferon-alpha follicular helper T-cellsPharmacologySettore MED/12 - Gastroenterologiabusiness.industryInterleukinsInterferon-alphaT-Lymphocytes Helper-InducerHepatitis CHepatitis C ChronicMiddle AgedViral LoadPrognosismedicine.diseaseImmunohistochemistryRecombinant ProteinsCD4 Lymphocyte CountInfectious DiseasesLiverImmunologyCohortRNA ViralImmunohistochemistryDrug Therapy CombinationFemalehcv immunohistochemistryInterferonsbusinessCohort studymedicine.drug
researchProduct

Chronic hepatitis C: the viral load per liver cell before treatment as a new marker to predict long-term response to IFN-α therapy

1998

Abstract Background/Aims: So far, there are no reliable parameters that can predict the long-term sustained response to treatment with interferon-α in patients with chronic hepatitis C. In this study, we have developed a semi-quantitative method to determine the viral load per liver cell and have correlated this factor with the outcome of hepatitis C patients treated with interferon-α. Methods: Hepatitis C virus RNA levels were measured in serum, peripheral blood mononuclear cells and liver cells of randomly chosen hepatitis C patients before treatment with interferon-α ( n =37). The number of cells present in the liver biopsies was determined by a polymerase chain reaction-based quantitati…

AdultMaleGenotypeHepatitis C virusmedicine.medical_treatmentHepacivirusmedicine.disease_causePeripheral blood mononuclear cellPredictive Value of TestsHumansMedicineSerotypingInterferon alfaAgedHepatitis ChronicHepatologybusiness.industryLiver cellAge FactorsInterferon-alphaHepatitis CMiddle AgedViral LoadPrognosismedicine.diseaseHepatitis CTreatment OutcomeCytokineLiverImmunologyLeukocytes MononuclearRNA ViralFemaleViral diseasebusinessViral loadmedicine.drugJournal of Hepatology
researchProduct

HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated…

2003

Abstract Background/Aims HVR-1 quasispecies composition and evolution were investigated in patients chronically infected with genotype 1b HCV, treated with PEG-IFN α2b or STD-IFN α2b plus RBV. Methods HVR-1 heterogeneity was assessed by calculating nucleotidic complexity, diversity, synonymous (S) and non-synonymous (NS) substitutions at baseline, after 4 weeks of therapy ( T 1) and at follow-up ( T 18). Evolution of viral quasispecies was analysed by constructing phylogenetic trees. Results No correlation of baseline viremia with heterogeneity was observed. Nucleotidic complexity was lower in patients showing early virological response, and tended to be inversely correlated to viral load d…

AdultMaleHepacivirusHepatitis C virusViremiaHepacivirusViral quasispeciesInterferon alpha-2medicine.disease_causeAntiviral AgentsVirusPolyethylene GlycolsEvolution MolecularViral Proteinschemistry.chemical_compoundFlaviviridaeDrug Resistance ViralRibavirinmedicineHumansPhylogenyHepatologybiologyRibavirinGenetic VariationInterferon-alphaHepatitis C ChronicMiddle AgedPrognosisbiology.organism_classificationmedicine.diseaseVirologyRecombinant ProteinschemistryImmunologyDrug Therapy CombinationFemaleViral loadHCV Interferon Quasispecies HVR-1
researchProduct